Sign up USA
Proactive Investors - Run By Investors For Investors

Patrys' positive pre-clinical data puts it on the podium of ASX Top % Gainers

Patrys has traded over 27 million shares in the first hour of the session.
Patrys' positive pre-clinical data puts it on the podium of ASX Top % Gainers
The leading ASX % gainers in morning trade

Patrys Ltd's (ASX:PAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.

Studies in multiple pre-clinical models of cancer have demonstrated the ability of Patrys’ proprietary humanized antibody, PAT-DX1 to be taken-up and to kill cancer cells.

This confirms the successful humanization and de-immunization of 3E10-derived antibody fragments with conserved structural properties and enhanced in vitro activity.

Company Name Code Last Change Volume
Maximus Resources Ltd MXR $0.002 100% 653,760
Patrys Ltd PAB $0.007 75% 27,240,497
Emperor Range Group Ltd ERX $0.060 71.43% 8,400
Bass Oil Ltd BAS $0.003 50% 1,200,000
Pancontinental Oil & Gas NL PCL $0.004 33.33% 148,097,873
Shareroot Ltd SRO $0.009 28.57% 10,354,000
Strandline Resources Ltd STA $0.005 25% 400,000
UUV Aquabotix Ltd UUV $0.120 25% 269,478
Chapmans Ltd CHP $0.005 25% 650,000
NTM Gold Ltd NTM $0.055 22.22% 33,800

 

View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

White board with marketing ideas
March 13 2017
There was a bit of a wobble in the run-up to the Brexit vote and shortly after it, but the group's 'buy, build & grow' strategy is taking shape
marketing
November 15 2017
Next Fifteen Communications expects another strong performance in the second half
learning symbol on a keyboard
January 16 2017
The English language learning specialist is confident it can kick on in the coming year

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use